Mostrar el registro sencillo

dc.contributor.authorCastañeda, Santos
dc.contributor.authorVicente-Rabaneda, Esther F.
dc.contributor.authorGarcía- Castañeda, Noelia
dc.contributor.authorPrieto-Peña, Diana
dc.contributor.authorDessein, Patrick H.
dc.contributor.authorGonzález-Gay Mantecón, Miguel Ángel 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2020-04-27T15:11:46Z
dc.date.available2021-01-01T03:45:14Z
dc.date.issued2020
dc.identifier.issn1744-666X
dc.identifier.issn1744-8409
dc.identifier.urihttp://hdl.handle.net/10902/18496
dc.description.abstractIntroduction: Increased cardiovascular (CV) morbidity and mortality is observed in inflammatory joint diseases (IJDs) such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. However, the management of CV disease in these conditions is far from being well established.Areas covered: This review summarizes the main epidemiologic, pathophysiological, and clinical risk factors of CV disease associated with IJDs. Less common aspects on early diagnosis and risk stratification of the CV disease in these conditions are also discussed. In Europe, the most commonly used risk algorithm in patients with IJDs is the modified SCORE index based on the revised recommendations proposed by the EULAR task force in 2017.Expert opinion: Early identification of IJD patients at high risk of CV disease is essential. It should include the use of complementary noninvasive imaging techniques. A multidisciplinary approach aimed to improve heart-healthy habits, including strict control of classic CV risk factors is crucial. Adequate management of the underlying IJD is also of main importance since the reduction of disease activity decreases the risk of CV events. Non-steroidal anti-inflammatory drugs may have a lesser harmful effect in IJD than in the general population, due to their anti-inflammatory effects along with other potential beneficial effects.es_ES
dc.description.sponsorshipMA González-Gay’s research has been supported by grants from “Fondo de Investigaciones Sanitarias” PI06/0024, PS09/00748, PI12/00060, PI15/00525,PI18/00043, and RD12/0009/0013 and RD16/0012 (RIER) from “Instituto de Salud Carlos III” (ISCIII) (Spain), co-funded by FEDER funds.es_ES
dc.format.extent14 p.es_ES
dc.language.isoenges_ES
dc.publisherTaylor & Francises_ES
dc.rights© Taylor & Francis. This is an Accepted Manuscript of an article published by Taylor & Francis in Expert Rev Clin Immunol on Epub 2019 Dec 10, available online: http://www.tandfonline.com/10.1080/1744666X.2019.1699058es_ES
dc.sourceExpert Rev Clin Immunol. 2020 Jan;16(1):23-36es_ES
dc.subject.otherAnkylosing Spondylitises_ES
dc.subject.otherCardiovascular Diseasees_ES
dc.subject.otherCardiovascular Risk Factorses_ES
dc.subject.otherInflammatory Joint Diseaseses_ES
dc.subject.otherPreventiones_ES
dc.subject.otherPsoriatic Arthritises_ES
dc.subject.otherRheumatoid Arthritises_ES
dc.titleUnmet needs in the management of cardiovascular risk in inflammatory joint diseaseses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1080/1744666X.2019.1699058es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1080/1744666X.2019.1699058
dc.type.versionacceptedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo